Wang Yimeng, Ma Ailing, Zhao Ningmin, et al. Blood Concentration Monitoring and Clinical Application of Sirolimus in Children. [J]. 28(1):10-13(2022)
DOI:
Wang Yimeng, Ma Ailing, Zhao Ningmin, et al. Blood Concentration Monitoring and Clinical Application of Sirolimus in Children. [J]. 28(1):10-13(2022) DOI: 10.13407/j.cnki.jpp.1672-108X.2022.01.003.
Blood Concentration Monitoring and Clinical Application of Sirolimus in Children
Objective: To probe into the blood concentration of sirolimus in children
and to investigate the correlation between blood concentration and related laboratory indicators
so as to provide more clinical evidence for the rational use of sirolimus. Methods: Fifty-four pediatric patients treated with sirolimus were enrolled
and the basic information
blood concentration of sirolimus (CSRL)
liver function and neutrophil (NEU) and other related information were recorded. Results: The blood concentration of sirolimus in children was (8.7±5.9) ng/mL
16.7% of the children with blood concentration of <4.0 ng/mL
62.9% of the children with blood concentration from 4.0 to 12.0 ng/mL
and 20.4 % of children with blood drug concentration >12.0 ng/mL. Sirolimus was used for tuberous sclerosis in 51.9% of children
with the lowest blood concentration of sirolimus 4.6 (3.9) ng/mL when compared with other diseases. In the treatment of tuberous sclerosis
60.7% of children were treated with antiepileptic drugs in combination
of which the proportion of drug combination of valproic acid was the highest (57.1%). Aspartate aminotransferase (AST) was positively correlated with CSRL (r=0.458
P<0.05). In children with blood concentration >12.0 ng/mL
there was a linear increase in the rate of abnormal AST
alanine aminotransferase (ALT) and NEU. Conclusion: When sirolimus is used in children
it is even more important to monitor the blood concentration
blood routine and liver function on a timely and regular basis to fully implement the individualized dosing to ensure clinical efficacy.